Skip to main content

Advertisement

SpringerLink
Log in

Diagnostic and prognostic values of tissue hsa-miR-30c and hsa-miR-203 in prostate carcinoma

  • Original Article
  • Published:
Tumor Biology

Abstract

Prostate cancer (PCa) has become a prevalent malignant disease in males globally. Accumulating data suggested that hsa-microRNAs (miRNAs) could be potential biomarkers for tumor diagnosis due to their important roles in the cell cycle. This study investigated the diagnostic and prognostic values of hsa-miR-203 and hsa-miR-30c in PCa tissues. There were 44 pathologically confirmed PCa patients who were enrolled in this study. Tissue samples were collected from both tumor tissues and adjacent normal tissues. RNA was extracted and the expression levels of hsa-miR-203 and hsa-miR-30c in tumor and normal tissues were compared. The receiver operating characteristic (ROC) curves were plotted to evaluate the reliability of hsa-miR-203 and hsa-miR-30c in detecting PCa. All subjects in this study were followed up by 36 months, and the Kaplan-Meier method was conducted to investigate the survival status of PCa patients. The average relative expressions of hsa-miR-203 and hsa-miR-30c in tumor tissues were significantly different from those in adjacent normal tissues (P < 0.001), and the predictive power of the two hsa-miRNAs for PCa prognosis was reliable. Besides that, the average survival times of low-hsa-miR-30c and high-hsa-miR-203 groups were significantly lower than those of the corresponding groups with the log-rank P of 0.015 and 0.023, respectively. In summary, our study suggested that both hsa-miR-203 and hsa-miR-30c are potential biomarkers for detection and prognosis of PCa.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer J Int du cancer. 2010;127:118–26.

    Article  CAS  Google Scholar 

  2. Casanova-Salas I, Rubio-Briones J, Calatrava A, Mancarella C, Masia E, Casanova J, Fernandez-Serra A, Rubio L, Ramirez-Backhaus M, Arminan A, Dominguez-Escrig J, Martinez F, Garcia-Casado Z, Scotlandi K, Vicent MJ, Lopez-Guerrero JA. Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy. J Urol 2014

  3. Peyromaure EM, Mao K, Sun Y, Xia S, Jiang N, Zhang S, et al. A comparative study of prostate cancer detection and management in China and in France. Can J Urol. 2009;16:4472–7.

    PubMed  Google Scholar 

  4. Roberts WW, Bergstralh EJ, Blute ML, Slezak JM, Carducci M, Han M, et al. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology. 2001;57:1033–7.

    Article  CAS  PubMed  Google Scholar 

  5. Xiong SW, Lin TX, Xu KW, Dong W, Ling XH, Jiang FN, et al. MicroRNA-335 acts as a candidate tumor suppressor in prostate cancer. Pathol Oncol Res. 2013;19:529–37.

    Article  CAS  PubMed  Google Scholar 

  6. Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, et al. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics. 2010;3:8.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Catalona WJ, Partin AW, Finlay JA, Chan DW, Rittenhouse HG, Wolfert RL, et al. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/ml and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology. 1999;54:220–4.

    Article  CAS  PubMed  Google Scholar 

  8. Emiliozzi P, Longhi S, Scarpone P, Pansadoro A, DePaula F, Pansadoro V. The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen. J Urol. 2001;166:845–50.

    Article  CAS  PubMed  Google Scholar 

  9. Roehl KA, Antenor JA, Catalona WJ. Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng./ml. range. J Urol. 2002;168:922–5.

    Article  PubMed  Google Scholar 

  10. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007;13:7053–8.

    Article  CAS  PubMed  Google Scholar 

  11. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302–9.

    Article  PubMed  Google Scholar 

  12. Gonzales JC, Fink LM, Goodman Jr OB, Symanowski JT, Vogelzang NJ, Ward DC. Comparison of circulating microRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer. 2011;9:39–45.

    Article  PubMed  Google Scholar 

  13. Mavridis K, Stravodimos K, Scorilas A. Downregulation and prognostic performance of microRNA 224 expression in prostate cancer. Clin Chem. 2013;59:261–9.

    Article  CAS  PubMed  Google Scholar 

  14. Loeb S, Partin AW. Review of the literature: PCA3 for prostate cancer risk assessment and prognostication. Rev Urol. 2011;13:e191–195.

    PubMed  PubMed Central  Google Scholar 

  15. Yaman Agaoglu F, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N, et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol. 2011;32:583–8.

    Article  CAS  PubMed  Google Scholar 

  16. Haj-Ahmad TA, Abdalla MA, Haj-Ahmad Y. Potential urinary miRNA biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients. J Cancer Educ. 2014;5:182–91.

    Article  CAS  Google Scholar 

  17. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997–1006.

    Article  CAS  PubMed  Google Scholar 

  18. Casanova-Salas I, Rubio-Briones J, Fernandez-Serra A, Lopez-Guerrero JA. MiRNAs as biomarkers in prostate cancer. Clin Transl Oncol. 2012;14:803–11.

    Article  CAS  PubMed  Google Scholar 

  19. Deng Y, Huang Z, Xu Y, Jin J, Zhuo W, Zhang C, et al. MiR-215 modulates gastric cancer cell proliferation by targeting RB1. Cancer Lett. 2014;342:27–35.

    Article  CAS  PubMed  Google Scholar 

  20. Yuxia M, Zhennan T, Wei Z. Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. J Cancer Res Clin Oncol. 2012;138:2045–50.

    Article  PubMed  Google Scholar 

  21. Mar-Aguilar F, Luna-Aguirre CM, Moreno-Rocha JC, Araiza-Chavez J, Trevino V, Rodriguez-Padilla C, et al. Differential expression of miR-21, miR-125b and miR-191 in breast cancer tissue. Asia Pac J Clin Oncol. 2013;9:53–9.

    Article  PubMed  Google Scholar 

  22. Guo F, Tian J, Lin Y, Jin Y, Wang L, Cui M. Serum microrna-92 expression in patients with ovarian epithelial carcinoma. J Int Med Res. 2013;41:1456–61.

    Article  CAS  PubMed  Google Scholar 

  23. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, et al. Micro-rna profiling in kidney and bladder cancers. Urol Oncol. 2007;25:387–92.

    Article  CAS  PubMed  Google Scholar 

  24. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One. 2009;4, e6229.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Saini S, Majid S, Dahiya R. Diet, microRNAs and prostate cancer. Pharm Res. 2010;27:1014–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. He HC, Zhu JG, Chen XB, Chen SM, Han ZD, Dai QS, et al. MicroRNA-23b downregulates peroxiredoxin III in human prostate cancer. FEBS Lett. 2012;586:2451–8.

    Article  CAS  PubMed  Google Scholar 

  27. Viticchie G, Lena AM, Latina A, Formosa A, Gregersen LH, Lund AH, et al. MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines. Cell Cycle. 2011;10:1121–31.

    Article  CAS  PubMed  Google Scholar 

  28. Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stoppler H, et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res. 2011;71:550–60.

    Article  CAS  PubMed  Google Scholar 

  29. Ling XH, Han ZD, Xia D, He HC, Jiang FN, Lin ZY, et al. MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer. Mol Biol Rep. 2014;41:2779–88.

    Article  CAS  PubMed  Google Scholar 

  30. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol. 2011;45:355–60.

    Article  CAS  PubMed  Google Scholar 

  31. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Benaich N, Woodhouse S, Goldie SJ, Mishra A, Quist SR, Watt FM. Rewiring of an epithelial differentiation factor, miR-203, to inhibit human squamous cell carcinoma metastasis. Cell Rep. 2014;9:104–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Noguchi S, Kumazaki M, Mori T, Baba K, Okuda M, Mizuno T, Akao Y. Analysis of microrna-203 function in CREB/MITF/RAB27a pathway: comparison between canine and human melanoma cells. Vet Comp Oncol 2014

  34. Boll K, Reiche K, Kasack K, Morbt N, Kretzschmar AK, Tomm JM, et al. MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene. 2013;32:277–85.

    Article  CAS  PubMed  Google Scholar 

  35. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009;11:1487–95.

    Article  CAS  PubMed  Google Scholar 

  36. Fang Y, Shen H, Cao Y, Li H, Qin R, Chen Q, et al. Involvement of miR-30c in resistance to doxorubicin by regulating YWHAZ in breast cancer cells. Braz J Med Biol Res. 2014;47:60–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Kong X, Xu X, Yan Y, Guo F, Li J, Hu Y, et al. Estrogen regulates the tumour suppressor miRNA-30c and its target gene, MTA-1, in endometrial cancer. PLoS One. 2014;9, e90810.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Ren Q, Liang J, Wei J, Basturk O, Wang J, Daniels G, et al. Epithelial and stromal expression of miRNAs during prostate cancer progression. Am J Transl Res. 2014;6:329–39.

    PubMed  PubMed Central  Google Scholar 

  39. Kim JH, Lee JM, Nam HJ, Choi HJ, Yang JW, Lee JS, et al. SUMOylation of pontin chromatin-remodeling complex reveals a signal integration code in prostate cancer cells. Proc Natl Acad Sci U S A. 2007;104:20793–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Wang XS, Shankar S, Dhanasekaran SM, Ateeq B, Sasaki AT, Jing X, et al. Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discovery. 2011;1:35–43.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Wang H, Fan L, Wei J, Weng Y, Zhou L, Shi Y, et al. Akt mediates metastasis-associated gene 1 (MTA1) regulating the expression of e-cadherin and promoting the invasiveness of prostate cancer cells. PLoS One. 2012;7, e46888.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Kao CJ, Martiniez A, Shi XB, Yang J, Evans CP, Dobi A, et al. MiR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene. 2014;33:2495–503.

    Article  CAS  PubMed  Google Scholar 

  43. Zhang K, Dai L, Zhang B, Xu X, Shi J, Fu L, Chen X, Li J, Bai Y. MiR-203 is a direct transcriptional target of E2F1 and causes G1 arrest in esophageal cancer cells. J Cell Physiol 2014

  44. Zhong K, Chen K, Han L, Li B. MicroRNA-30b/c inhibits non-small cell lung cancer cell proliferation by targeting rab18. BMC Cancer. 2014;14:703.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This study is supported by the National Science Foundation of China (NSFC 81570053), Shanghai Science and Technology Commission Foundation of Key Medical Research (034119868 and 09411951600), and Research Foundation of Shanghai Municipal Health Bureau (20134034).

Author information

Authors and Affiliations

  1. Department of Pathology, Tongji Hospital, Tongji University School of Medicine, No. 389 Xincun Road, Shanghai, 200065, China

    Ziling Huang, Long Zhang, Xianghua Yi & Xiaoting Yu

  2. Department of Pathology, Labway Clinical Laboratory Shanghai Ltd, Shanghai, 200000, China

    Ziling Huang

Authors
  1. Ziling Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Long Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xianghua Yi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaoting Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Xianghua Yi or Xiaoting Yu.

Ethics declarations

Conflicts of interest

None

Additional information

Ziling Huang and Long Zhang are first co-authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, Z., Zhang, L., Yi, X. et al. Diagnostic and prognostic values of tissue hsa-miR-30c and hsa-miR-203 in prostate carcinoma. Tumor Biol. 37, 4359–4365 (2016). https://doi.org/10.1007/s13277-015-4262-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4262-9

Keywords

Search

Navigation